Page 663 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 29 Tumors of the Male Reproductive System 641

169. Hayden DW, Klausner JS, Waters DJ: Prostatic leiomyosarcoma in 192. Mochizuki H, Breen M: Sequence analysis of RAS and RAF
a dog, J Vet Diagn Invest 11:283–286, 1999. mutation hot spots in canine carcinoma, Vet Comp Oncol 15:
170. Bacci B, Vignoli M, Rossi F, et al.: Primary prostatic leiomyosar- 1598–1605, 2017.
VetBooks.ir coma with pulmonary metastases in a dog, J Am An Hosp Assoc 193. Kollermann J, Albrecht H, Schlomm T, et al.: Activating BRAF
gene mutations are uncommon in hormone refractory prostate can-
46:103–106, 2010.
cer in Caucasian patients, Oncol Lett 1:729–732, 2010.
171. Hayden DW, Bartges JW, Bell FW, et al.: Prostatic hemangiosar-
coma in a dog: clinical and pathologic findings, J Vet Diagn Invest 194. Mochizuki H, Breen M: Comparative aspects of BRAF mutations
4:2009–2011, 1992. in canine cancers, Vet Sci 2:231–245, 2015.
172. Gilson SD, Miller RT, Hardie EM, et al.: Unusual prostatic mass 195. Taylor BS, Schultz N, Hieronymus H, et al.: Integrative
in a dog, J Am Vet Med Assoc 200:702–704, 1992. genomic profiling of human prostate cancer, Cancer Cell 18:
173. LeRoy BE, Northrup N: Prostate cancer in dogs: comparative and 11–22, 2010.
clinical aspects, Vet J 180:149–162, 2009. 196. Salmaninejad A, Ghadami S, Dizaji MZ, et al.: Molecular charac-
174. Dore M, Chevalier S, Sirois J: Estrogen-dependent induction of terization of KRAS, BRAF, and EGFR genes in cases with prostatic
cyclooxygenase-2 in the canine prostate in vivo, Vet Pathol 42:100– adenocarcinoma; reporting bioinformatics description and recur-
103, 2005. rent mutations, Clin Lab 61:749–759, 2015.
175. Shidaifat F, Daradka M, Al-Omari R: Effect of androgen ablation 197. Tremblay C, Dore M, Bochsler PN, et al.: Induction of prostaglan-
on prostatic cell differentiation in dogs, Endocr Res 30:327–334, din G/H synthase-2 in a canine model of spontaneous prostatic
2004. adenocarcinoma, J Natl Cancer Inst 91:1398–1403, 1999.
176. Grieco V, Patton V, Romussi S, et al.: Cytokeratin and vimentin 198. Mohammed SI, Coffman K, Glickman NW, et al.: Prostaglandin
expression in normal and neoplastic canine prostate, J Comp Pathol E2 concentrations in naturally occurring canine cancer, Prostaglan-
129:78–84, 2003. dins Leukot Essent Fatty Acids 64:1–4, 2001.
177. Cooley DM, Waters DJ: Skeletal metastasis as the initial clinical 199. Mohammed SI, Khan KN, Sellers RS, et al.: Expression of cyclo-
manifestation of metastatic carcinoma in 19 dogs, J Vet Intern Med oxygenase-1 and 2 in naturally-occurring canine cancer, Prostaglan-
12:288–293, 1998. dins Leukot Essent Fatty Acids 70:479–483, 2004.
178. Durham SK, Dietze AE: Prostatic adenocarcinoma with and with- 200. Sorenmo KU, Goldschmidt MH, Shofer FS, et al.: Evaluation of
out metastasis to bone in dogs, J Am Vet Med Assoc 188:1432–1436, cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of
1986. cyclooxygenase inhibitors in canine prostatic carcinoma, Vet Comp
179. Waters DJ, Cooley DM, Allen DK, et al.: Host age influences the Oncol 2:13–23, 2004.
biological behavior of cancer: studies in pet dogs with naturally 201. Keller ET, Zhang J, Cooper CR, et al.: Prostate carcinoma skeletal
occurring malignancies, Gerontologist 38(110), 1998. metastases: cross-talk between tumor and bone, Cancer Metastasis
180. Ross RK, Pike MC, Coetzee GA, et al.: Androgen metabolism and Rev 20:333–349, 2001.
prostate cancer: establishing a model of genetic susceptibility, Can- 202. Sellers RS, LeRoy BE, Blomme EA, et al.: Effects of transform-
cer Res 58:4497–4504, 1998. ing growth factor-beta1 on parathyroid hormone-related protein
181. Matsuzaki P, Cogliati B, Sanches DS, et al.: Immunohistochemi- mRNA expression and protein secretion in canine prostate epithe-
cal characterization of canine prostatic intraepithelial neoplasia, lial, stromal, and carcinoma cells, Prostate 58:366–373, 2004.
J Comp Pathol 142:84–88, 2010. 203. LeRoy BE, Sellers RS, Rosol TJ: Canine prostate stimulates
182. Fonseca-Alves CE, Kobayashi PE, Palmieri C, et al.: Investigation osteoblast function using the endothelin receptors, Prostate 59:
of c-KIT and Ki67 expression in normal, preneoplastic and neo- 148–156, 2004.
plastic canine prostate, BMC Vet Res 13:380, 2017. 204. Simmons JK, Hildreth 3rd BE, Supsavhad W, et al.: Animal mod-
183. Kobayashi PE, Fonseca-Alves CE, Rivera-Calderon LG, et al.: els of bone metastasis, Vet Pathol 52:827–841, 2015.
Deregulation of E-cadherin, beta-catenin, APC and caveolin-1 205. Hibberd C, Cossigny DA, Quan GM: Animal cancer models of
expression occurs in canine prostate cancer and metastatic pro- skeletal metastasis, Cancer Growth Metastasis 6:23–34, 2013.
cesses, Res Vet Sci 118:254–261, 2018. 206. Ylitalo EB, Thysell E, Jernberg E, et al.: Subgroups of castration-
184. Servian P, Celma A, Planas J, et al.: Clinical significance of prolif- resistant prostate cancer bone metastases defined through an inverse
erative inflammatory atrophy finding in prostatic biopsies, Prostate relationship between androgen receptor activity and immune
75:1669–1675, 2015. response, Eur Urol 71:776–787, 2017.
185. Servian P, Celma A, Planas J, et al.: Clinical significance of prolif- 207. Nordstrand A, Bovinder Ylitalo E, Thysell E, et al.: Bone cell activ-
erative inflammatory atrophy in negative prostatic biopsies, Prostate ity in clinical prostate cancer bone metastasis and its inverse relation
76:1501–1506, 2016. to tumor cell androgen receptor activity, Int J Mol Sci 19, 2018.
186. Fonseca-Alves CE, Kobayashi PE, Rivera-Calderon LG, et al.: Evi- 208. Leav I, Ling GV: Adenocarcinoma of the canine prostate, Cancer
dence of epithelial-mesenchymal transition in canine prostate can- 22:1329–1345, 1968.
cer metastasis, Res Vet Sci 100:176–181, 2015. 209. Lee-Parritz DE, Lamb CR: Prostatic adenocarcinoma with osseous
187. Fonseca-Alves CE, Kobayashi PE, Laufer-Amorim R: Evaluation of metastases in a dog, J Am Vet Med Assoc 192:1569–1572, 1988.
NKX3.1 and C-MYC expression in canine prostatic cancer, Res Vet 210. Barsanti JA, Finco DR: Canine prostatic disease, Vet Clin North Am
Sci 118:365–370, 2018. 16:587–599, 1986.
188. Palmieri C, Mancini M, Benazzi C, et al.: Heat shock protein 90 is 211. Johnston SD, Kamolpatana K, Root-Kustritz MV, et al.:
associated with hyperplasia and neoplastic transformation of canine Prostatic disorders in the dog, Anim Reprod Sci 61:
prostatic epithelial cells, J Comp Pathol 150:393–398, 2014. 405–415, 2000.
189. Gallardo F, Lloreta J, Garcia F, et al.: Immunolocalization of 212. Liptak JM, Brutscher SP, Monnet E, et al.: Transurethral resection
androgen receptors, estrogen alpha receptors, and estrogen beta in the management of urethral and prostatic neoplasia in 6 dogs,
receptors in experimentally induced canine prostatic hyperplasia, Vet Surg 33:505–516, 2004.
J Androl 30:240–247, 2009. 213. Powe JR, Canfield PJ, Martin PA: Evaluation of the cyto-
190. Gallardo F, Mogas T, Baro T, et al.: Expression of androgen, oes- logic diagnosis of canine prostatic disorders, Vet Clin Pathol 33:
trogen alpha and beta, and progesterone receptors in the canine 150–154, 2004.
prostate: differences between normal, inflamed, hyperplastic and 214. Feeney DA, Johnston GR, Klausner JS, et al.: Canine prostatic dis-
neoplastic glands, J Comp Pathol 136:1–8, 2007. ease—comparison of radiographic appearance with morphologic
191. Mochizuki H, Kennedy K, Shapiro SG, et al.: BRAF mutations in and microbiologic findings: 30 cases (1981-1985), J Am Vet Med
canine cancers, PloS One 10:e0129534, 2015. Assoc 190:1018–1026, 1987.